“The breadth of these data showcases our strategy to advance diverse modalities for difficult-to-treat cancers,” stated Jay Bradner, M.D., executive vice president, Research and Development, and chief scientific officer at Amgen. “The results presented at ESMO demonstrate our leadership in oncology, highlighting significant advancements with investigational and established therapies. By leveraging an in-depth understanding of cancer biology and precision therapeutics, we can target dominant drivers of disease with unparalleled accuracy.”
Key presentations include:
– Initial findings from the Phase 1b trial of LUMAKRAS plus Vectibix in combination with FOLFIRI in first-line patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
– Phase 1 dose escalation and initial dose expansion data from AMG 193 selected for a presidential symposium session.
– First-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer (mCRPC).
For more information on the Amgen abstracts and presentation details, please refer to the provided information.
